Your browser doesn't support javascript.
loading
Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.
Gombash, S E; Manfredsson, F P; Mandel, R J; Collier, T J; Fischer, D L; Kemp, C J; Kuhn, N M; Wohlgenant, S L; Fleming, S M; Sortwell, C E.
  • Gombash SE; 1] Graduate Program in Neuroscience, University of Cincinnati, Cincinnati, OH, USA [2] Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Manfredsson FP; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Mandel RJ; Department of Neuroscience, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA.
  • Collier TJ; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Fischer DL; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Kemp CJ; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Kuhn NM; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Wohlgenant SL; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
  • Fleming SM; Departments of Psychology and Neurology, University of Cincinnati, Cincinnati, OH, USA.
  • Sortwell CE; Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Gene Ther ; 21(7): 682-93, 2014 Jul.
Article en En | MEDLINE | ID: mdl-24807806
ABSTRACT
Intrastriatal injection of recombinant adeno-associated viral vector serotype 2/1 (rAAV2/1) to overexpress the neurotrophic factor pleiotrophin (PTN) provides neuroprotection for tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc), increases THir neurite density in the striatum (ST) and reverses functional deficits in forepaw use following 6-hydroxydopamine (6-OHDA) toxic insult. Glial cell line-derived neurotrophic factor (GDNF) gene transfer studies suggest that optimal neuroprotection is dependent on the site of nigrostriatal overexpression. The present study was conducted to determine whether enhanced neuroprotection could be accomplished via simultaneous rAAV2/1 PTN injections into the ST and SN compared with ST injections alone. Rats were unilaterally injected in the ST alone or injected in both the ST and SN with rAAV2/1 expressing either PTN or control vector. Four weeks later, all rats received intrastriatal injections of 6-OHDA. Rats were euthanized 6 or 16 weeks relative to 6-OHDA injection. A novel selective total enumeration method to estimate nigral THir neuron survival was validated to maintain the accuracy of stereological assessment. Long-term nigrostriatal neuroprotection and functional benefits were only observed in rats in which rAAV2/1 PTN was injected into the ST alone. Results suggest that superior preservation of the nigrostriatal system is provided by PTN overexpression delivered to the ST and restricted to the ST and SN pars reticulata and is not improved with overexpression of PTN within SNpc neurons.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sustancia Negra / Proteínas Portadoras / Citocinas / Fármacos Neuroprotectores / Enfermedades Neurodegenerativas / Cuerpo Estriado Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sustancia Negra / Proteínas Portadoras / Citocinas / Fármacos Neuroprotectores / Enfermedades Neurodegenerativas / Cuerpo Estriado Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2014 Tipo del documento: Article